85-1560-95　MOG, aa35-55, Control Peptide (Myelin Oligodendrocyte Glycoprotein) 100ug　M9758-08M

特徴

• Control peptide for M9758-08K (affinity puriifed) and M9758-08L (antiserum).
• Myelin-oligodendrocyte glycoprotein (MOG) is a member of the immunoglobulin (Ig) superfamily, exclusively expressed in the central nervous system (CNS). MOG is an intrinsic membrane protein characterized by a N-terminal extracellular immunoglobulin- like variable (Ig-like V-type) domain, two hydrophobic transmembrane domains and a cytoplasmic C-terminal region. The N-terminal MOG domain has strong homology with the N- terminus of butyrophilin, a protein expressed in the lactating mammary gland. Human MOG gene is localized to chromosome 6p22-p21.3 (band C of mouse chromosome 17) at the distal end of the MHC class Ib region. Despite the similar names, oligodendrocyte-myelin glycoprotein (OMG) is a separate protein encoded within a large intron of the NF1 gene. The 2 glycoproteins are associated specifically with oligodendrocytes and myelin, but have quite different roles in myelinogenesis and are structurally unrelated. MOG is an intrinsic membrane molecule with 2 transmembrane domains, whereas OMG is anchored in the outer leaflet of the plasma membrane through a glycophospholipid tail. OMG belongs to the family of proteins with a series of tandem leucine-rich repeats, while MOG is a member of the Ig superfamily.
• MOG contains nine exons and eight separating introns, giving rise to at least eight alternatively spliced variants encoding for the MOG-alpha1-4 and MOG-beta 1-4 isoforms (16-26kD). The different MOG isoforms may interact to form homo- and heterodimers and trimers (55 and 78kD). During the last step of myelinogenesis, MOG is expressed in the CNS on the outermost surface (external lamella) of mature myelin sheaths and on the cell surface of myelinating oligodendrocytes. MOG is thought to function as a regulator of oligodendrocyte microtubule stability and as a mediator of interactions between myelin and the immune system in the complement cascade. Although MOG is a relatively minor component of the myelin membrane, it is a primary auto- antigen target involved in the pathogenesis of immune-mediated demyelinating diseases including experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis.
• The MOG 35-55 peptide is an immunodominant epitope of MOG that induces strong T and B cell responses. A single injection of this peptide fragment can produce an exacerbating-remitting neurologic disease with extensive plaque-like demyelination, which may serve as a model for investigating multiple sclerosis.
• Source:Synthetic peptide corresponding to 35-55aa from mouse MOG.
• Molecular Weight:~3kD
• Applications:Suitable for use in ELISA and Antibody Blocking. Not suitable for Western Blot. Other applications not tested.
• Recommended Dilution:ELISA: 5-10ug control peptide per 1ug of aff pure IgG or 1ul antiserumOptimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.